Summary
[China Resources Double Crane and Ligand Corporation of the United States cooperate to develop oral small molecule drugs for the treatment of new coronary pneumonia]China Resources Pharmaceutical official micro-message, a few days ago, China Resources Double Crane Innovation Division and the United States Ligand Pharmaceutical Corporation (NASDAQ: LGND) reached an agreement to jointly develop a An oral small molecule RNA polymerase inhibitor drug for the treatment of novel coronavirus pneumonia COVID-19. The project is currently in the pre-clinical research stage and will use Ligand’s BEPro technology to carry out research and development. In the future, China Resources Double Crane will have the right to obtain the exclusive right to develop and commercialize this drug in major Asian regions. This is the second cross-border innovative drug project of China Resources Double Crane Innovation Division since its establishment at the beginning of the year. It is reported that the antiviral drugs developed by BEPro technology have the characteristics of good oral bioavailability and increased drug concentration in the lungs, and have potential clinical therapeutic value for the development of small-molecule oral new crown drugs.
China Resources PharmaceuticalOfficial WeChat, a few days ago,China Resources Double CraneThe Innovation Division and Ligand Pharmaceuticals (NASDAQ:LGND) of the United States have reached an agreement to jointly develop an oral small molecule RNA polymerase inhibitor drug for the treatment of novel coronavirus pneumonia COVID-19.
The project is currently in the pre-clinical research stage and will use Ligand’s BEPro technology to carry out research and development.
future,China Resources Double CraneWill be entitled to the exclusive development and commercialization rights of this drug in major Asian regions.This isChina Resources Double CraneThe Innovation Division is the second cross-border innovative drug project since its establishment at the beginning of the year. It is reported that the antiviral drugs developed by BEPro technology have the characteristics of good oral bioavailability and increased drug concentration in the lungs, and have potential clinical therapeutic value for the development of small-molecule oral new crown drugs.
(Article source: e company)
.